10 studies found for:    Open Studies | "Carcinoma, Merkel Cell"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Merkel Cell"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting MSB0010718C in Subjects With Merkel Cell Carcinoma
Condition: Carcinoma, Merkel Cell
Intervention: Drug: MSB0010718C
2 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
3 Recruiting A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Biological: GLA-SE
4 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
5 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
6 Recruiting Dose Escalation Study to Investigate Safety, PK and Anti-tumor Activity of Pasireotide in Patients With Metastatic Melanoma or Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Intervention: Drug: Pasireotide sub-cutaneous formulation
7 Recruiting Merkel Positron Emission Tomography (PET) Protocol
Condition: Merkel Cell Carcinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
8 Recruiting Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Radiation: radiation therapy;   Biological: recombinant interferon beta;   Biological: MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine;   Biological: aldesleukin;   Other: laboratory biomarker analysis
9 Recruiting Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy;   Other: laboratory biomarker analysis
10 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years